Pal-GHK vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Pal-GHKGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- Extended (lipid depot in stratum corneum)
- ~5 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 0.005–0.1% in formulation
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Once or twice daily
- Once weekly, subcutaneous
- Key Benefits
- Stimulates collagen I and III synthesis in dermis
- Reduces the appearance of fine lines and wrinkles
- Improves skin elasticity and firmness
- Inhibits collagenase (MMP-1) to preserve existing collagen
- Enhances wound healing and skin repair
- Well-tolerated in anti-aging serums and creams
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Generally very well-tolerated
- Rare skin irritation at very high concentrations
- Possible formulation-dependent comedogenicity
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —